2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1853

Rheumatoid Arthritis Patients’ Experiences of Medication Side Effects and Subsequent Decision Making about Medications
Abstract Number: 1227

Rheumatoid Arthritis-Associated Interstitial LUNG Disease: Clinical Spectrum of A Large Cohort From A Respiratory Referral Center
Abstract Number: 2452

Rheumatoid Arthritis-Associated PTPN22 Modulates Toll-Like Receptor-Mediated, Type 1 Interferon-Dependent Innate Immunoregulation
Abstract Number: 421

Rheumatoid Factor, Not Antibodies to Citrullinated Proteins, Are Associated with High Disease Activity
Abstract Number: 1885

Rheumatologists’ Ultrasound Confidence and Interpretation of Normal Anatomy Are Improved by a Cadaver Based Sonoanatomy Course
Abstract Number: 1546

Rhinosinusits and Nasal Polyps in the Diagnosis and Follow up of Patients with Eosinophilic Granulomatosis with Polyangitis (ex-Churg Strauss Syndrome)
Abstract Number: 1729

Ribophorin II Is Involved in the Tissue Factor Expression Mediated by Phosphatidylserine-Dependent Antiprothrombin Antibody On Monocytes
Abstract Number: 813

Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials
Abstract Number: 152

Rilonacept for Gout Flare Reduction: Estimation of Number Needed to Treat to Benefit (NNTB)
Abstract Number: 606

Risk Factors Associated with Cervical Human Papillomavirus Infection in Women with Systemic Lupus Erythematosus: The Role of Rituximab
Abstract Number: 630

Risk Factors Associated with Early Central Nervous System Damage Detected Through Diffusion Tensor Imaging (DTI) in Patients with Systemic Lupus Erythematosus
Abstract Number: 1397

Risk Factors Associated with Early Central Nervous System Damage Detected Through Perfusion MRI in Patients with Systemic Lupus Erythematosus
Abstract Number: 696

Risk Factors for EARLY Mortality in Scleroderma Patients: A Report From the EULAR Scleroderma Trials and Research Group (EUSTAR) Database
Abstract Number: 307

Risk Factors for Poor Outcomes in Hospitalized Patients with Pediatric Systemic Lupus Erythematosus
Abstract Number: 363

Risk Factors for Radiographic Progression During TNF-Inhibitor Treatment in 932 Rheumatoid Arthritis Patients Treated in Clinical Practice: Results From the Nationwide Danish Danbio Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].